Celltrion Pharm, Inc. (068760.KQ)
KRW 61300.0
(-3.01%)
KRW 61300.0
(-3.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 264.97 Billion KRW | 9.07% |
| 2022 | 242.93 Billion KRW | -19.8% |
| 2021 | 302.91 Billion KRW | 23.88% |
| 2020 | 244.51 Billion KRW | 30.1% |
| 2019 | 187.94 Billion KRW | 4.76% |
| 2018 | 179.4 Billion KRW | 3.32% |
| 2017 | 173.64 Billion KRW | 6.94% |
| 2016 | 162.37 Billion KRW | -28.91% |
| 2015 | 228.41 Billion KRW | 115998.69% |
| 2014 | 196.73 Million KRW | 1.97% |
| 2013 | 192.94 Million KRW | 11.01% |
| 2012 | 173.79 Million KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 258.79 Billion KRW | -0.99% |
| 2024 Q1 | 261.38 Billion KRW | -1.35% |
| 2023 Q4 | 264.97 Billion KRW | -0.74% |
| 2023 Q1 | 257.56 Billion KRW | 6.02% |
| 2023 Q2 | 250.92 Billion KRW | -2.58% |
| 2023 FY | 264.97 Billion KRW | 9.07% |
| 2023 Q3 | 266.95 Billion KRW | 6.39% |
| 2022 FY | 242.93 Billion KRW | -19.8% |
| 2022 Q3 | 245.12 Billion KRW | -3.0% |
| 2022 Q2 | 252.69 Billion KRW | -9.24% |
| 2022 Q1 | 278.43 Billion KRW | -8.08% |
| 2022 Q4 | 242.93 Billion KRW | -0.89% |
| 2021 Q3 | 268.46 Billion KRW | 10.59% |
| 2021 Q1 | 267.14 Billion KRW | 107831.19% |
| 2021 FY | 302.91 Billion KRW | 23.88% |
| 2021 Q4 | 302.91 Billion KRW | 12.83% |
| 2021 Q2 | 242.75 Billion KRW | -9.13% |
| 2020 FY | 244.51 Billion KRW | 30.1% |
| 2020 Q1 | 205.62 Million KRW | 7.68% |
| 2020 Q2 | 215.74 Million KRW | 4.92% |
| 2020 Q3 | 238.27 Million KRW | 10.44% |
| 2020 Q4 | 247.51 Million KRW | 3.88% |
| 2019 Q3 | 180.32 Million KRW | -4.03% |
| 2019 Q2 | 187.89 Million KRW | 7.09% |
| 2019 FY | 187.94 Billion KRW | 4.76% |
| 2019 Q1 | 175.45 Million KRW | -3.81% |
| 2019 Q4 | 190.94 Million KRW | 5.89% |
| 2018 Q2 | 175.73 Million KRW | 3.98% |
| 2018 Q1 | 169.01 Million KRW | -4.32% |
| 2018 FY | 179.4 Billion KRW | 3.32% |
| 2018 Q4 | 182.4 Million KRW | 0.19% |
| 2018 Q3 | 182.06 Million KRW | 3.6% |
| 2017 FY | 173.64 Billion KRW | 6.94% |
| 2017 Q1 | 157.69 Million KRW | -4.64% |
| 2017 Q3 | 168.4 Million KRW | 2.98% |
| 2017 Q2 | 163.53 Million KRW | 3.7% |
| 2017 Q4 | 176.64 Million KRW | 4.89% |
| 2016 FY | 162.37 Billion KRW | -28.91% |
| 2016 Q2 | 176.67 Million KRW | -9.81% |
| 2016 Q1 | 195.89 Million KRW | -15.03% |
| 2016 Q3 | 182.11 Million KRW | 3.08% |
| 2016 Q4 | 165.37 Million KRW | -9.19% |
| 2015 Q4 | 230.53 Million KRW | -2.31% |
| 2015 FY | 228.41 Billion KRW | 115998.69% |
| 2015 Q1 | 219.63 Million KRW | 11.64% |
| 2015 Q3 | 235.99 Million KRW | 4.65% |
| 2015 Q2 | 225.5 Million KRW | 2.67% |
| 2014 Q1 | 194.39 Million KRW | 0.75% |
| 2014 Q2 | 204.88 Million KRW | 5.4% |
| 2014 Q3 | 210.27 Million KRW | 2.63% |
| 2014 Q4 | 196.73 Million KRW | -6.44% |
| 2014 FY | 196.73 Million KRW | 1.97% |
| 2013 Q3 | 180.43 Million KRW | -0.84% |
| 2013 Q1 | 170.11 Million KRW | -2.12% |
| 2013 Q2 | 181.96 Million KRW | 6.97% |
| 2013 Q4 | 192.94 Million KRW | 6.93% |
| 2013 FY | 192.94 Million KRW | 11.01% |
| 2012 Q4 | 173.79 Million KRW | 0.0% |
| 2012 FY | 173.79 Million KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | -398.095% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | -561.95% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 34.941% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | -0.614% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -1466.168% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -1109.136% |
| Boditech Med Inc. | 30.48 Billion KRW | -769.204% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | -290.683% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -2871.0% |
| Huons Co., Ltd. | 206.87 Billion KRW | -28.087% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -1107.413% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | -593.806% |